A study to evaluate the effect of Calcium on the duration of blue light therapy required for the treatment of babies with jaundice
Phase 2
- Conditions
- Health Condition 1: P599- Neonatal jaundice, unspecified
- Registration Number
- CTRI/2022/03/041203
- Lead Sponsor
- Dr Arnab Ghorui
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
All newborns of either sex with neonatal jaundice requiring phototherapy as per AAP(American Academic of Pediatrics)/NICE(National Institute for Health & Care Excellence) guidelines
Exclusion Criteria
1.Newborns kept on nil per mouth due to any cause.
2.Newborns with conjugated hyperbilirubinemia. (Direct bilirubin >2mg/dl or direct bilirubin is >20% of total serum bilirubin).
3.Newborns with renal anomalies on antenatal ultrasound.
4.Newborn at any point of time requiring calcium supplements or therapy for any medical indication.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To compare the rate of fall of total serum bilirubin in both the groups. <br/ ><br>Timepoint: Starting point- TSB at the beginning of phototherapy <br/ ><br> <br/ ><br>Thereafter, TSB every 6th hourly <br/ ><br> <br/ ><br>End point-When TSB comes 2md/dl below the phototherapy cut off for that hours of life <br/ ><br>
- Secondary Outcome Measures
Name Time Method Incidence of rebound hyperbilirubinemia in proportion/percentageTimepoint: 6 hours after stoppage of phototherapy;Rate of fall of bilirubin in mg/dl/hour.Timepoint: Total serum bilirubin 6 hours after starting of phototherapy, then 12th hourly till total serum bilirubin comes 2mg/dl below the phototherapy cutoff for that hours of life